L-ornithine L-aspartate — Competitive Intelligence Brief

L-ornithine L-aspartate (L-ornithine L-aspartate) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ammonia-lowering agent. Area: Hepatology / Gastroenterology.

marketed Ammonia-lowering agent Urea cycle enzymes (ornithine transcarbamylase, carbamoyl phosphate synthetase); glutamine synthetase Hepatology / Gastroenterology Small molecule

Target snapshot

L-ornithine L-aspartate (L-ornithine L-aspartate) — Medical University of Graz. L-ornithine L-aspartate enhances ammonia detoxification by promoting urea cycle function and glutamine synthesis in hepatic encephalopathy.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L-ornithine L-aspartate TARGET	L-ornithine L-aspartate	Medical University of Graz	marketed	Ammonia-lowering agent	Urea cycle enzymes (ornithine transcarbamylase, carbamoyl phosphate synthetase); glutamine synthetase
Ornithine aspartate granule	Ornithine aspartate granule	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Ammonia-lowering agent
L-ornithine-L-aspartate plus latulose	L-ornithine-L-aspartate plus latulose	Qurratul Ain Jamil	marketed	Ammonia-lowering agent combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ammonia-lowering agent class)

1. Medical University of Graz · 1 drug in this class
2. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class